|This Slide: #48 of 100|
Slide #48. Baxter International Inc. — Chatham Therapeutics
Baxter International Inc. (NYSE:BAX)
Baxter International Inc. (NYSE:BAX) and Chatham Therapeutics, LLC, today announced that Baxter has agreed to acquire all of Chatham's outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham's developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.
Baxter International, through its subsidiaries, provides a portfolio of healthcare products, including acute and chronic dialysis therapies; sterile intravenous solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision. Co. manages its business based on three geographic segments: Americas (North and South America), Europe, Middle East and Africa and Asia-Pacific.
Baxter International SEC Filing Email Alerts Service
Open the BAX Page at The Online Investor »
Buy (3.17 out of 4)
(ranked lower than approx. 53% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite